keyword
MENU ▼
Read by QxMD icon Read
search

wet-amd

keyword
https://www.readbyqxmd.com/read/28726777/humanin-g-hng-protects-age-related-macular-degeneration-amd-transmitochondrial-arpe-19-cybrids-from-mitochondrial-and-cellular-damage
#1
Sonali Nashine, Pinchas Cohen, Marilyn Chwa, Stephanie Lu, Anthony B Nesburn, Baruch D Kuppermann, M Cristina Kenney
Age-related macular degeneration (AMD) ranks third among the leading causes of visual impairment with a blindness prevalence rate of 8.7%. Despite several treatment regimens, such as anti-angiogenic drugs, laser therapy, and vitamin supplementation, being available for wet AMD, to date there are no FDA-approved therapies for dry AMD. Substantial evidence implicates mitochondrial damage and retinal pigment epithelium (RPE) cell death in the pathogenesis of AMD. However, the effects of AMD mitochondria and Humanin G (HNG), a more potent variant of the mitochondrial-derived peptide (MDP) Humanin, on retinal cell survival have not been elucidated...
July 20, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28652696/no-improvement-in-injection-frequency-or-in-visual-outcome-over-time-in-two-cohorts-of-patients-from-the-same-swedish-county-treated-for-wet-age-related-macular-degeneration
#2
Marion Schroeder, Lena Rung, Monica Lövestam-Adrian
BACKGROUND: Although ranibizumab has been used for the treatment of wet age-related macular degeneration (AMD) since 2007, real-world studies still report undertreatment resulting in a less favorable visual outcome. In this study, two different time cohorts of patients treated with ranibizumab for wet AMD in routine care were analyzed to observe whether there was a change over time regarding visual outcome, injection frequency, and quality of life (QoL). METHODS: We compared patients with treatment-naïve wet AMD in two observational follow-up cohorts 2007-2010 (n=50 patients) and 2009-2013 (n=26)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28643712/comparison-of-macular-pigment-optical-density-in-patients-with-dry-and-wet-age-related-macular-degeneration
#3
Ayhan Ozyurt, Nilufer Kocak, Pınar Akan, Ozlem Gursoy Calan, Taylan Ozturk, Mahmut Kaya, Eyup Karahan, Suleyman Kaynak
AIM: The aim of the study was to evaluate the macular pigment optical density (MPOD) levels in patients with wet age-related macular degeneration (AMD), dry AMD, and also in healthy controls. SETTINGS AND DESIGN: This study was conducted at Department of Ophthalmology, and the study design was a prospective study. PATIENTS AND METHODS: Forty-eight patients with wet AMD, 51 patients with dry AMD, and 50 controls were included in the study. All patients were naive to both previous lutein or zeaxanthin administration and any previous intravitreal injections...
June 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28643528/modulating-release-of-ranibizumab-and-aflibercept-from-thiolated-chitosan-based-hydrogels-for-potential-treatment-of-ocular-neovascularization
#4
Miguel Moreno, Poh Yih Pow, Tan Su Teng Tabitha, Sonali Nirmal, Andreas Larsson, Krishna Radhakrishnan, Jayabalan Nirmal, Soo Tng Quah, Susana Geifman Shochat, Rupesh Agrawal, Subbu Venkatraman
BACKGROUND: This paper describes the synthesis of thiolated chitosan-based hydrogels with varying degrees of crosslinking that has been utilized to modulate release kinetics of two clinically relevant FDA-approved anti-VEGF protein drugs, ranibizumab and aflibercept. These hydrogels have been fabricated into disc shaped structures for potential use as patches on ocular surface. METHODS: Protein conformational changes and aggregation after loading and release was evaluated by circular dichroism (CD), steady-state tryptophan fluorescence spectroscopy, electrophoresis and size-exclusion chromatography (SEC)...
July 3, 2017: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/28641277/association-of-the-cfh-y402h-polymorphism-with-the-1-year-response-of-exudative-amd-to-intravitreal-anti-vegf-treatment-in-the-brazilian-population
#5
Flavio Mac Cord Medina, Augusto Alves Lopes da Motta, Walter Yukihiko Takahashi, Pedro Carlos Carricondo, Mario Martins Dos Santos Motta, Monica B Melo, Jose Paulo C Vasconcellos
AIM: Evidence of the relationship between the polymorphism of the complement factor H (CFH) gene at position 402 (Y402H) and the response to the treatment of wet AMD is controversial. The aim of this study was to compare the functional and morphological 1-year evolution of patients with exudative AMD treated with antivascular endothelial growth factor (VEGF) drugs with the CFH Y402H polymorphism in the Brazilian population. METHODS: Forty-six patients treated for wet AMD with bevacizumab or ranibizumab in a pro re nata regimen were included...
June 23, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28613225/macular-degeneration-and-aspirin-use
#6
Kent W Small, Christine A Garabetian, Fadi S Shaya
PURPOSE: To review current literature of the benefits that aspirin provides for patients' cardiovascular health compared with the risk of AMD worsening. METHODS: We performed a review and critically analyzed six cardiovascular and four ophthalmological trials regarding risks and benefits of aspirin use. The prospective randomized cardiovascular trials had a cumulative 167,580 while the 3 smaller ophthalmological data sets had a cumulative 12,015 subjects. RESULTS: The reviewed meta-analysis literature demonstrated a statistically significant 32% reduction in the risk of nonfatal stroke with regular aspirin users...
January 23, 2017: Retina
https://www.readbyqxmd.com/read/28579747/prevalence-of-and-risk-factors-for-age-related-macular-degeneration-in-nepal-the-bhaktapur-retina-study
#7
Raba Thapa, Sanyam Bajimaya, Govinda Paudyal, Shankar Khanal, Stevie Tan, Suman S Thapa, Ger van Rens
AIM: This study aimed to explore the prevalence of and risk factors for age-related macular degeneration (AMD) in an elderly population in Nepal. SUBJECTS AND METHODS: This is a population-based, cross-sectional study. A sample size of 2,100 was calculated. A total of 1,860 (88.6%) subjects aged >60 years were enrolled for the study from 30 clusters in the district. Detailed history, visual acuity, and anterior segment and posterior segment examinations were performed...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28557377/wet-amd-on-a-chip-modeling-outer-blood-retinal-barrier-in-vitro
#8
Minhwan Chung, Somin Lee, Byung Joo Lee, Kyungmin Son, Noo Li Jeon, Jeong Hun Kim
Choroidal neovascularization (CNV) in the retinal pigment epithelium (RPE)-choroid complex constituting outer blood retinal barrier (oBRB) is a critical pathological step in various ophthalmic diseases, which results in blindness, such as wet type age-related macula degeneration. Current in vitro experimental models using petri dishes or transwell are unable to study CNV morphogenesis. Here, a unique organotypic eye-on-a-chip model is described that mimics the RPE-choroid complex in vitro. This model consists of an RPE monolayer and adjacent perfusable blood vessel network, which is supporting barrier function of oBRB...
May 29, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28551897/-phacoemulsification-in-eyes-with-neovascular-age-related-macular-degeneration-amd
#9
Daniel Rappoport, Mordechai Goldberg, Amir Bukelman, Haya Katz, Lital Goldberg, Ayala Pollack
INTRODUCTION: Age-related macular degeneration (AMD) is the leading cause of blindness in the western world. The debate continues over the safety of cataract surgery in the setting of neovascular (wet) AMD. This retrospective review aims to describe our experience in treating patients with wet AMD, who underwent cataract surgery by phacoemulsification. METHODS: We prepared a retrospective chart review of patients treated in our clinic between the years 2006 - 2013...
February 2017: Harefuah
https://www.readbyqxmd.com/read/28548650/aflibercept-in-age-related-macular-degeneration-evaluating-its-role-as-a-primary-therapeutic-option
#10
REVIEW
M Ashraf, A A R Souka
The recent VIEW studies have demonstrated the non-inferiority of monthly and bi-monthly aflibercept in the management of wet age related macular degeneration (AMD) compared with ranibizumab. However, the current data are limited mainly to fixed dosing regimens with few studies looking at flexible dosing regimens of aflibercept in wet AMD. In addition, recent data from the VIEW 96 week extension has shown that patients being shifted from fixed dosing regimens to PRN have shown a drop in visual acuity and increase in central macular thickness...
May 26, 2017: Eye
https://www.readbyqxmd.com/read/28542257/long-term-results-after-limited-macular-translocation-surgery-for-wet-age-related-macular-degeneration
#11
Hisaaki Oshima, Takeshi Iwase, Kohei Ishikawa, Kentaro Yamamoto, Hiroko Terasaki
PURPOSE: To evaluate the long-term results of limited macular translocation (LMT) surgery with radial chorioscleral outfolding in patients with wet age-related macular degeneration (AMD) and subfoveal choroidal neovascularization (CNV). In addition, to identify the factors associated with the final best-corrected visual acuity (BCVA). METHODS: The medical records of 20 eyes of 20 consecutive patients (65.2±9.8 years) who had undergone LMT for the treatment of wet AMD and were followed for at least 5 years, were reviewed...
2017: PloS One
https://www.readbyqxmd.com/read/28538392/maculopapular-rash-after-intravitreal-injection-of-an-antivascular-endothelial-growth-factor-aflibercept-for-treating-age-related-macular-degeneration-a-case-report
#12
Norihiro Nagai, Mari Ibuki, Hajime Shinoda, Kaori Kameyama, Kazuo Tsubota, Yoko Ozawa
RATIONALE: Aflibercept, an anti-vascular endothelial growth factor (VEGF) drug, is used for treatment of colon cancer as well as retinal diseases, including wet age-related macular degeneration (AMD). It is injected into the vitreous cavity of eyes for treatment of AMD. Although vascular suppression-including cardiovascular events-and local infection related to the injection procedure are well-known potential adverse events, pathological immune responses after intravitreal aflibercept (IVA) injection have not been described...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28526492/gene-therapy-for-the-long-term-treatment-of-wet-amd
#13
Elizabeth P Rakoczy
No abstract text is available yet for this article.
May 16, 2017: Lancet
https://www.readbyqxmd.com/read/28524715/prevalence-of-age-related-macular-degeneration-in-slovakia-and-associated-risk-factors-a-mobile-clinic-based-cross-sectional-epidemiological-survey
#14
Vladimir Krasnik, Jana Stefanickova, Ivajlo Popov, Jela Valaskova, Sandeep Saxena, Peter Kruzliak
PURPOSE: Age-related macular degeneration (AMD) is one of the leading causes of blindness in the elderly population. Although there are prevalence studies for AMD in Europe, data are scarce for the Slovakian population. METHODS: This was a prospective, multicenter, non-interventional, mobile clinic-based cross-sectional study that assessed age-specific prevalence of AMD in the Slovakian population and risk factors associated with AMD. The type of AMD was graded based on the international age-related maculopathy grading system; optical coherence tomography (OCT) was used for the differential diagnosis...
May 19, 2017: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/28491291/recent-advances-in-the-management-and-understanding-of-macular-degeneration
#15
REVIEW
Sepehr Bahadorani, Michael Singer
Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD.
2017: F1000Research
https://www.readbyqxmd.com/read/28486987/progress-of-stem-progenitor-cell-based-therapy-for-retinal-degeneration
#16
REVIEW
Zhimin Tang, Yi Zhang, Yuyao Wang, Dandan Zhang, Bingqiao Shen, Min Luo, Ping Gu
Retinal degeneration (RD), such as age-related macular degeneration (AMD) and retinitis pigmentosa, is one of the leading causes of blindness. Presently, no satisfactory therapeutic options are available for these diseases principally because the retina and retinal pigmented epithelium (RPE) do not regenerate, although wet AMD can be prevented from further progression by anti-vascular endothelial growth factor therapy. Nevertheless, stem/progenitor cell approaches exhibit enormous potential for RD treatment using strategies mainly aimed at the rescue and replacement of photoreceptors and RPE...
May 10, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28467791/dry-age-related-macular-degeneration-like-pathology-in-aged-5xfad-mice-ultrastructure-and-microarray-analysis
#17
Sung Wook Park, Sora Im, Hyoung Oh Jun, Kihwang Lee, Young-Jun Park, Jin Hyoung Kim, Woo Jin Park, Young-Hoon Lee, Jeong Hun Kim
Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. The two types of AMD are: dry and wet AMD. While laser-induced choroidal neovascularization has been used extensively in the studies of wet AMD, there is no established mouse model that fully recapitulates the cardinal features of dry AMD. A lack of appropriate mouse model for dry AMD has hampered the translational research on the pathogenesis of the disease and the development of therapeutic agents. We hypothesized that 5XFAD mice, an animal model for the study of Alzheimer's disease, can be used as a mouse model for dry AMD with regard to the amyloid beta (Aβ) related pathology...
June 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28452378/scharioth-macula-lens-a-new-intraocular-implant-for-low-vision-patients-with-stabilized-maculopathy-first-experience
#18
Jana Nekolova, Pavel Rozsival, Martin Sin, Nada Jiraskova
AIMS: To present the initial results of Scharioth Macula Lens (SML) implantation. The SML is a new add-on intraocular lens designed to increase uncorrected near visual acuity (UCVA) in patients with stabilized maculopathy. METHODS: Eight patients were included in the study. All met the indication criteria before SML implantation. An SML was implanted in the better seeing eye. Near and distance visual acuity were tested. Possible complications and patient complaints were recorded and patients were asked about their quality of vision after SML implantation...
April 26, 2017: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/28440245/pluripotent-stem-cells-a-therapeutic-source-for-age-related-macular-degeneration
#19
REVIEW
Sowmya Parameswaran, Subramanian Krishnakumar
Age-related macular degeneration (AMD) leads to progressive loss of central vision in the elderly. At a cellular level, there is aging of the retinal pigment epithelial (RPE) cells, and accumulation of lipofuscin that interferes with the proper functioning of RPE which eventually leads to apoptosis. Treatment depends on the stage of the disease. Wet AMD which has neovascularization is managed by local therapies such as laser photocoagulation and photodynamic therapy and is managed with injections of antivascular endothelial growth factor-based therapy...
March 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28435212/testing-the-clinical-value-of-multifocal-electroretinography-and-microperimetry-and-the-effects-of-intravitreal-therapy-with-ranibizumab-on-macular-function-in-the-course-of-wet-age-related-macular-degeneration-a-1-year-prospective-study
#20
Mihaela Reinsberg, Ralf-Dieter Hilgers, Inger Lüdeke, Khaled Nassar, Swaantje Grisanti, Salvatore Grisanti, Julia Lüke, Matthias Lüke
PURPOSE: To investigate the clinical value of multifocal electroretinography (mfERG) and microperimetry and the effects of intravitreal therapy with ranibizumab (Lucentis(®)) on macular function in the course of neovascular age-related macular degeneration (nAMD). MATERIALS AND METHODS: We conducted a prospective single-arm interventional cohort study with 20 nAMD patients older than 50 years. Examinations were scheduled monthly for 1 year during intravitreal therapy with ranibizumab...
2017: Clinical Ophthalmology
keyword
keyword
53816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"